Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about the effects of high blood glucose levels in the brain and assess if the changes seen in individuals with poorly control T2DM can be reversed with good glucose control. The main question\[s\] it aims to answer are: * To determine, whether abnormalities in brain glucose transport seen in individuals with uncontrolled diabetes, can be improved with better glucose control. * Assess which factors, (duration of diabetes mellitus (DM) and glycemic control) contribute to changes in glucose transport Participants will have: * A screening visit * placement of a continuous glucose monitor (CGM) 2 weeks before the first magnetic resonance spectroscopy (MRS) at week 0 * Additional visits/phone calls for intensification of diabetes management and nutrition visits * Second magnetic resonance spectroscopy (MRS) at week 12

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Nutrition visits — Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee
  • Other: Intensification of diabetes regimen — Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
  • Other: Continuous glucose monitor (CGM) — Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.

Primary Outcomes

  • Brain glucose concentration in the occipital cortex week 0 (week 0)
  • Brain glucose concentration in the occipital cortex week 12 (week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-19
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Elizabeth Sanchez Rangel, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Elizabeth Sanchez Rangel, MD
203-785-6430
elizabeth.sanchezrangel@yale.edu
Interventions
  • Behavioral: Nutrition visits — Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee
  • Other: Intensification of diabetes regimen — Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
  • Other: Continuous glucose monitor (CGM) — Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
Study Locations (1 sites)
Yale New Haven Hospital (YNHH) Research Unit (HRU), New Haven, Connecticut 06520 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18-60 * medical history for Type 2 diabetes * HbA1c \> 7.5%, BMI ≥18 kg/m2 * Be willing to adhere to the intensification of their diabetes regimen Exclusion Criteria: * Creatinine \> 1.5 mg/dL * Hgb \< 10 mg/dL, hematocrit of 37 % for males participants and 33 % for female participants * ALT \>3 x ULN * untreated thyroid disease, * uncontrolled hypertension * known neurological disorders * untreated psychiatric disorders * malignancy * bleeding disorders * current or recent steroid use in last 3 months * illicit drug use * for women: pregnancy, actively seeking pregnancy, or breastfeeding * inability to enter MRI/MRS (as per standard MRI safety guidelines).
Conditions Postpartum Depression
Phase NA
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this longitudinal study is to study the effects of a parenting skills group (Circle of Security Parenting, aka COSP) in mothers with postpartum depression. The main questions it aims to answer are: * Will changes in methylation of the OXTR rs53576 be apparent in mother and/or infant after having gone through the 8-week COSP program? * Will COSP participation be associated with improved symptoms of postpartum depression (over and above standard care), attachment style, and relational characteristics of the mother-infant dyad? * Will COSP participation be associated with changes in social behavior in the infant, and if so, do they persist throughout childhood? Participants will * Participate in an 8-week COSP program delivered remotely via Zoom. * Provide buccal swabs (mother and infant) to assess changes in methylation of OXTR rs53576 pre- versus post-intervention. * Complete a series of assessment questionnaires delivered remotely. * Videotape a play-based assessment in their home. * Receive infant developmental testing Researchers will compare characteristics of waitlist controls to those participating in the COSP program at the mid-way point of the program to see if the two groups differ.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Circle of Security Parenting program — The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.

Primary Outcomes

  • Change in methylation of OXTR receptor gene rs53576 (Time1 (baseline), Time4 (1 week post-intervention), Time5 (6 months post-intervention), Time6 (12 months post-intervention) Time7 (average 4.5 years post-intervention))
  • Changes in Beck Depression Inventory, Second Edition (BDI-II) Score (Time1 (baseline), Time2 (1 week pre-intervention), Time3 (week 5 of intervention), Time4 (1 week post-intervention), Time5 (6 months post-intervention), Time6 (12 months post-intervention), Time7 (average 4.5 years post-intervention))
  • Changes Postpartum Depression Screening Scale (PDSS) Score (Time1 (baseline), Time2 (1 week pre-intervention), Time3 (week 5 of intervention), Time4 (1 week post-intervention), Time5 (6 months post-intervention), Time6 (12 months post-intervention))
  • Changes in Dyadic Adjustment Scale (DAS) Score (Time1 (baseline), Time2 (1 week pre-intervention), Time3 (week 5 of intervention), Time4 (1 week post-intervention), Time5 (6 months post-intervention), Time6 (12 months post-intervention), Time7 (average 4.5 years post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-03
Completion: 2035-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Principal Investigators:
  • Sunny Stophaeros, MS (PRINCIPAL_INVESTIGATOR) - sunny.stophaeros@ucdenver.edu
Contact Information
Study Contact:
Sunny Stophaeros, MS
9253392971
sunny.stophaeros@ucdenver.edu
Caroline R Harrison, MPH
caroline.harrison@cuanschutz.edu
Sunny Stophaeros, MS
925-339-2971
sunny.stophaeros@ucdenver.edu
University of Colorado Denver
Interventions
  • Behavioral: Circle of Security Parenting program — The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
Study Locations (1 sites)
University of Colorado Denver, Denver, Colorado 80204 United States
Eligibility Criteria
Inclusion Criteria: * Mothers aged 18-50 years old with infants aged 3-14 months old * Mothers who are experiencing symptoms of depression and mothers who are not experiencing symptoms of depression (non-depressed controls) are encouraged to participate. (please note that mothers who are experiencing active depression and who are not already being treated under the care of a qualified healthcare provider (i.e. through therapy or psychopharmacological intervention) will be referred for such treatment prior to being enrolled in the study. This study is not a replacement for professional management of depression or other mental health symptoms. Exclusion Criteria: * Mothers with severe psychopathology (such as bipolar disorder, schizophrenia, personality disorders, among others) * Infants with major medical problems that may interfere with a mother's ability to participate in and benefit from the intervention
Conditions Anxiety Disorders and Symptoms, Depressi...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess a mobile app called MAYA for use in middle-aged and older adults with anxiety or mood disorders. The MAYA app is designed to teach coping skills for anxiety and depression that are drawn from cognitive behavioral therapy. Participants will be asked to use the app for at least two days a week, 20 minutes on each day, for six weeks. Participants will have weekly check-ins as well as longer assessments at the beginning of the study, week 3, week 6 (end of treatment), and week 12 (follow up). During assessments, participants will answer brief questionnaires designed to assess their symptoms and impressions of the app. The main hypotheses of the study are that participants will complete most of the assigned sessions and that they will rate their impressions of the app highly. The secondary hypotheses are that symptoms of depression and anxiety will decrease with use of the MAYA app.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: MAYA Mobile Application — The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.

Primary Outcomes

  • Acceptability of the MAYA application as measured by mean uMARS scores at Baseline (Week 1 (Baseline))
  • Acceptability of the MAYA application as measured by mean uMARS scores at Midpoint (Week 3 (Midpoint))
  • Acceptability of the MAYA application as measured by mean uMARS scores at Endpoint (Week 6 (Endpoint))
  • Feasibility of the MAYA application as measured by total number of sessions completed in the MAYA application at Endpoint (Week 6 (Endpoint))
  • Feasibility of the MAYA application as measured by total number of sessions completed in the MAYA application at Follow Up (Week 12 (Follow Up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-16
Completion: 2027-06
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Joseph S. Sanchez Foundation
Principal Investigators:
  • Jennifer Bress, Ph.D. (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Maddy Schier
(646) 289-5271
mas4019@med.cornell.edu
Zareen Mir
(646)-289-5271
zam4005@med.cornell.edu
Jennifer Bress, Ph.D
914.997.8683
jeb2061@med.cornell.edu
Weill Cornell Medicine
Interventions
  • Behavioral: MAYA Mobile Application — The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Age 40 or older * Primary diagnosis of an anxiety or depressive disorder as determined by a clinical severity rating score of 4 or greater on the Anxiety Disorders Interview Schedule (ADIS). * Mini Mental Status Exam (MMSE) no more than 1 SD below the mean score for patient's age and education. If the remote version of the MMSE is used (e.g. during an evaluation on Zoom), the remote MMSE score will be converted to a standard MMSE score. * Access to an Apple iPhone, iPad, or Android device. Exclusion Criteria: * Lifetime diagnosis of a bipolar or psychotic disorder. * Currently in cognitive behavior therapy. * Change in dose of a psychiatric medication in the past 12 weeks. * Initiation of psychotherapy in the past 12 weeks. * Intent or plan to attempt suicide.
Conditions Asthma, COPD, BOS
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Spirometry is now the gold standard technique for assessing lung function in humans. From the shape of a flow-volume curve measured while the patient, trained by the practitioner, performs forced breaths, the forced vital capacity (FVC) and the forced expiratory volume in one second (FEV1) can be deduced and the pulmonologist is able to detect and characterize respiratory diseases as well as to evaluate current treatments. This technique is non-invasive and simple. It is widely available, robust, reproducible and sensitive to intervention. However, it requires proactive cooperation from the patient and only measures global pulmonary ventilation, without locoregional information. An innovative strategy and an original study framework have been developed in the BioMaps laboratory to establish local maps of flow-volume curves across the lung and to jointly analyze ventilatory function and mechanical behavior at any point in the lung: 3D magnetic resonance spirometry. As respiratory mechanics fundamentally supports ventilatory function, this technique should open a new avenue to non-invasively explore lung function while providing a better diagnosis of regional lung diseases.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 1. Standard spirometry — Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
  • Diagnostic Test: 2. 3D dynamic lung MRI at UTE in prone and supine positions — Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
  • Drug: 3. Reversibility test with salbutamol — Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
  • Diagnostic Test: 4. 3D dynamic lung MRI at UTE in supine and prone position — Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.

Primary Outcomes

  • Correlation between (1) spontaneous expiratory volume in 1 s (SEV1) and tidal volume (TV) and (2) FEV1 and FVC (2 months)
  • Difference of expiratory volume in 1 s (SEV1) and tidal volume (TV) between the left and right lungs (2 months)
  • Difference in expiratory volume in 1 s (SEV1) and tidal volume (TV) for the anterior-posterior, inferior-superior and medial-lateral lung regions (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-26
Completion: 2028-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Commissariat A L'energie Atomique
Contact Information
Study Contact:
MARTINS Bernadette
+33169087460
bernadette.martins@cea.fr
MARTINS Bernadette
+33169087460
bernadette.martins@cea.fr
CEA | Service Hospitalier Fréderic Joliot
Interventions
  • Diagnostic Test: 1. Standard spirometry — Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
  • Diagnostic Test: 2. 3D dynamic lung MRI at UTE in prone and supine positions — Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
  • Drug: 3. Reversibility test with salbutamol — Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
  • Diagnostic Test: 4. 3D dynamic lung MRI at UTE in supine and prone position — Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
Study Locations (1 sites)
CEA | Service Hospitalier Fréderic Joliot, Orsay, France 91401 France
Eligibility Criteria
Inclusion Criteria: Generic inclusion criteria * Ability to understand the nature and objectives of the study * Ability to remain immobile in an MRI scanner in supine position for the entire duration of the acquisitions * Ability to give free and informed written consent Specific inclusion criteria for healthy volunteers * Age: 18-45 years * No known and diagnosed pulmonary pathology such as respiratory insufficiency, COPD, asthma or cancer * Ability to remain motionless in an MRI scanner in a prone position for a total of 50 min. * Non-smoker and non-smoker Specific inclusion criteria for asthma patients * Age: 18-80 years * Asthma of varying degrees of severity, depending on inhalation required to achieve control: * Diagnosis of asthma classified as moderate according to the Global initiative for asthma (GINA) guidelines for at least 6 months * Diagnosis of asthma classified as severe according to the Global initiative for asthma (GINA) guidelines for at least 6 months months with initiation of biotherapy planned by their pulmonologist * Non-smoker and non-vapourist Specific inclusion criteria for COPD patients * Age: 40-80 years * COPD of varying degrees of severity: * Diagnosis of COPD classified as moderate according to the Global initiative for chronic obstructive lung disease guidelines (GOLD 2: VEMS = 50-79%) * Diagnosis of COPD classified as severe according to the guidelines for chronic obstructive lung disease (GOLD 3: VEMS = 30-49%) Specific inclusion criteria for patients with bilateral lung transplants with BOS * Age: 18-90 years * Irreversible FEV1 \< 80% of baseline with FEV1/FVC ratio FEV1/FVC \< 0.7 * Absence of visible parenchymal opacity on CT scan (non inclusion of mixed RAS/CLAD) * Absence of significant bronchial stenosis (having required endoscopic endoscopic treatment) * No diaphragmatic involvement (established by sniff test under fluoroscopy fluoroscopy or diaphragmatic ultrasound) Specific inclusion criteria for patients with bilateral lung transplants without BOS * Age: 18-90 years * FEV1 \> 90% baseline for more than 24 months after the date of date of lung transplantation * Absence of significant bronchial stenosis (requiring endoscopic endoscopic treatment) * Absence of diaphragmatic impairment (established by sniff test under fluoroscopy or diaphragmatic ultrasound)
Conditions HER2-positive Breast Cancer
Phase PHASE2
Enrollment 188
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

ExteNET study explored neratinib prolong anti-HER2 therapy after trastuzumab therapy found that it can improve disease-free survival in patients with lymph nodes positive; In addition, the subgroup of patients with residual tumors after neoadjuvant therapy was found to improve the survival. However, no conclusive conclusions were reached. However, since the study was carried out early so only trastuzumab treatment was used, it is urgent to carry out research that is more in line with current clinical practice and bring more benefits to patients. To explore whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER2-positive breast cancer after treatment with trastuzumab and pertuzumab or T-DM1.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib — Pyrotinib after anti-HER2 therapy(Trastuzumab combined with Pertuzumab or T-DM1)

Primary Outcomes

  • Invasive Disease-free Survival (iDFS) at year 2 (From enrollment until time of events up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-04-08
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 188 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Principal Investigators:
  • Xiaoan Liu, Professor (PRINCIPAL_INVESTIGATOR) - Jiangsu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University
Contact Information
Study Contact:
Xiaoan Liu, Professor
025-68308162
liuxiaoan@126.com
Xiaoan Liu, Professor
025-68308162
liuxiaoan@126.com
JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: Pyrotinib — Pyrotinib after anti-HER2 therapy(Trastuzumab combined with Pertuzumab or T-DM1)
Study Locations (1 sites)
JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Subjects voluntarily participate in this study and sign the informed consent form; 2. Female or male patients, aged ≥ 18 years, and ≤75 years; 3. ECOG PS score: 0-1; 4. Patients with HER2+ early or locally advanced breast cancer confirmed by histopathology: HER2-positive is defined by standard of 3+ by immunohistochemical staining (IHC), or 2+ by immunohistochemical staining (IHC) but positive by in situ hybridization (ISH). 5. Stage II through IIIC HER-2 positive breast cancer with node positive disease after surgery. 6. Been treated for early breast cancer with standard of care duration of trastuzumab combined with pertuzumab or T-DM1. 7. Could have been treated neoadjuvantly but have not reached pathologic complete response. Exclusion Criteria: 1. metastatic disease (Stage IV) or inflammatory breast cancer 2. Previous or current history of malignant neoplasms, except for curatively treated:Basal and squamous cell carcinoma of the skin,Carcinoma in situ of the cervix. 3. Clinically relevant cardiovascular disease:Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110); 4. A history of allergy to the drugs in this study; 5. Unable or unwilling to swallow tablets 6. History of gastrointestinal disease with diarrhea as the major symptom.
Conditions Acute Lung Injury, Prevention
Phase PHASE2
Enrollment 214
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the occurrence of minor radiation lung injury with the use of more novel drugs and subsequent salvage treatment may aggravate the radiation injury. This study intends to conduct a randomized, double-blind, single-center clinical study of pirfenidone versus placebo in the prevention of acute radiation induced lung injury after breast cancer surgery

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Drug: Pirfenidone/Placebo — Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.

Primary Outcomes

  • Changes in lung injury grading on chest computerized tomography within 3 months after radiotherapy (4 weeks and 12 weeks after radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-16
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 214 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Medical University Union Hospital
Collaborators: Beijing Continent Pharmaceutical Co, Ltd.
Principal Investigators:
  • Yong Yang, Doctor (PRINCIPAL_INVESTIGATOR) - Director of the radiotherapy department
Contact Information
Study Contact:
Yong Yang, Doctor
18813019084
dr_yangyong1983@163.com
Daxin Huang, Master
13655913399
1660579075@qq.com
Interventions
  • Drug: Pirfenidone/Placebo — Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
Study Locations (1 sites)
Fujian Medical University Union Hospital, Fuzhou, Fujian China
Eligibility Criteria
Inclusion Criteria: * To be enrolled in this study, patients must meet all of the following inclusion criteria: 1. Breast invasive carcinoma or ductal carcinoma in situ or lobular carcinoma in situ confirmed by histology; 2. Age 18-75, female; 3. The physical state score of the Eastern Tumor Cooperative Group (ECOG) was 0-2; 4. Patients meeting the indications of postoperative radiotherapy and neoadjuvant chemotherapy: clinical stage 3 or above or postoperative ypT3-T4 or N+; Non-neoadjuvant chemotherapy patients: postoperative pathological staging of pT3-T4 or pN2 or above, or positive for upper and lower clavicle and lymph nodes in the internal milk region, or positive for clinical consideration; For patients with pT1-2N1, postoperative adjuvant radiotherapy should be determined based on the patient's age, tumor grade, incisal margin, number of positive lymph nodes, molecular typing, past complications, and patient's intention. 5. Radiotherapy regimen was chest wall + supraclavicular 40Gy/15f after root modification, or whole milk ± upper and lower clavicular 40Gy/15f after breast preservation, tumor bed simultaneous supplement 50Gy/15f; 6. All screening period laboratory tests should be performed in accordance with protocol requirements and within 28 days prior to enrollment. The values of laboratory tests performed by screening must meet the following criteria: blood routine check all meet the following criteria: A. Hb≥90g/L; B. ANC≥1.5×109/L; C. PLT≥70×109/L; biochemical examination all meet the following criteria: TBIL \< 1.5× upper limit of normal range (ULN); ALT and AST≤2.5 x ULN; Serum Cr≤1.25×ULN or endogenous creatinine clearance ≥45 mL/min (Cockcroft-Gault formula) 7. Women who are at risk of becoming pregnant must undergo a negative serum pregnancy test within 7 days before the first dose and be willing to use a highly effective method of contraception during the trial period and 120 days after the last dose of the test drug. Male subjects with a partner of a woman of reproductive age should be surgically sterilized or consent to a highly effective method of contraception during the trial period and 120 days after the last test drug administration; 8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: * Patients with any of the following criteria were not enrolled in this study 1. History and complications A. male breast cancer patients; B. Did not meet the conditions of large segmentation radiotherapy (upper and lower clavicular lymph node metastasis, internal milk lymph node metastasis, the patient refused large segmentation radiotherapy); C. The subject has any active, known, or suspected autoimmune disease. To admit subjects who are in a stable state and do not require systemic immunosuppressive therapy; D. The patient is participating in another clinical study or less than 4 weeks after the end of the previous clinical study; E. Patients with a known or highly suspected history of interstitial pneumonia; Or may interfere with the detection or management of suspected drug-related pulmonary toxicity; F. A history of other malignant tumors; Except in patients who have had potentially curable therapy and have not had disease recurrence for 5 years since treatment began; G. Pregnant women and patients with mental illness; H. Prior treatment with radiotherapy, chemotherapy, etc.; I. Patients with active tuberculosis should be excluded; J. Severe acute or chronic lung infections requiring systemic treatment; K. Patients with obvious blood coughing or daily hemoptysis of half a teaspoon (2.5ml) or more in the 2 months before randomization; L. Patients with heart failure (New York Heart Association standard Class III or IV), poor coronary artery disease control or arrhythmia, or a history of myocardial infarction in the 6 months prior to screening despite receiving appropriate medication. 2. Physical examination and laboratory examination A. A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS); B. untreated active hepatitis (hepatitis B: HBsAg positive with HBV DNA≥ 500 IU/mL; Hepatitis C: HCV RNA positive and abnormal liver function); Combined with hepatitis B and hepatitis C co-infection. 3. As determined by the investigator, the patient may have other factors that may lead to the termination of the study, such as other serious diseases or serious abnormalities in laboratory tests or other factors that may affect the safety of the subjects, or family or social factors such as the collection of test data and samples.
Conditions Breast Cancer, Radiotherapy Side Effect
Phase PHASE2
Enrollment 65
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Ultra-fractionated radiation therapy — 5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.

Primary Outcomes

  • The rate of patients who develop radiation-associated acute toxicity (≥ 2 degree) (until 12 weeks from the completion of postoperative radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-10-25
Completion: 2030-10-25
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Shu-Lian Wang, M.D.
8610-87788290
wangsl@cicams.ac.cn
Hao Jing, M.D.
8610-87788281
owletskim@163.com
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Radiation: Ultra-fractionated radiation therapy — 5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
Study Locations (1 sites)
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021 China
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with invasive or non-invasive breast cancer; 2. The patients have undergone breast-conserving surgery or mastectomy with axillary sentinel nodal biopsy or dissection; 3. Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery). 4. No distant metastasis; 5. Life expectancy ≥6 months; 6. Organ function is fine (Hemoglobin ≥100g/L, leukocyte ≥2×109/L, neutrophil ≥1×109/L, platelet ≥80×109/L; Creatinine 1.5 mg/dl or less; Alanine aminotransferase/aspartate aminotransferase ≤2.5×UNL.); 7. Patients are willing to cooperate to follow up; 8. Patients should sign the informed consent; 9. Women of childbearing age need effective contraception. Exclusion Criteria: 1. Biopsy proven ipsilateral supraclavicular, infraclavicular or internal mammary nodal involvement. 2. Concurrent or previous neuropathy overlapping with the radiation volume or brachial plexus injury; 3. Patients who had radiotherapy to the ipsilateral breast, lymph-drainage regions or adjacent areas before; 4. Concurrent active connective tissue disease; 5. Other malignancies, which affect patient life expectancy (except adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder neoplasms (no more than T1), early stage thyroid carcinoma); 6. Severe comorbidities or active disease (Poorly controlled heart disease: New York Classification of Cardiac Function ≥ Grade 2, active coronary heart disease, unstable angina pectoris, arrhythmia requiring medical treatment/persistent refractory hypertension; Myocardial infarction, stroke within six months; Poorly controlled diabetes persists. Fasting blood glucose ≥ 10mmol/L, 2 hours postprandial blood glucose ≥ 13 mmol/L. Poorly controlled psychosis develops or worsens within six months; Active infection; Positive for antibodies to HIV). 7. Pregnant or breast-feeding.
Conditions Depression
Phase Not Applicable
Enrollment 2500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will provide data for evaluating the psychometric characteristics of the tests assessing cognitive flexibility, including their (1) internal consistency, (2) feasibility and tolerability, their (3) convergent and discriminant validity of cognitive and affective constructs such as those introduced to understand mental disorders, and (4) sensitivity (and correspondence) to individual differences. For these tests to be useful in studying clinical conditions, they must show adequate reliability, validity, and sensitivity in large samples of convenience.

Design

Study type: Observational Observational model: Case Crossover Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Computational dissociation of the causes of cognitive rigidity in depression — involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform

Primary Outcomes

  • Relationship of cognitive rigidity to depressive symptoms (1 hour)
  • Relationship between environmental volatility and cognitive rigidity (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-15
Completion: 2027-05-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Alexander Herman (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Matthew Maple
612-946-1424
maple036@umn.edu
Matthew Maple
612-946-1424
maple036@umn.edu
University of Minnesota
Interventions
  • Diagnostic Test: Computational dissociation of the causes of cognitive rigidity in depression — involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * Adults 18 years or older * English-speaking * Live in the U.S. * Have access to an internet connected computer * Users of the mTurk and Prolific survey website Exclusion Criteria: * NA

Freiburg TIPS Registry

NCT05782556
Recruiting
Conditions Liver Cirrhosis, Portal Hypertension, No...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial. Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) — For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient

Primary Outcomes

  • Transplantation-free survival (01/01/2023-31/12/2033)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2034-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Freiburg
Principal Investigators:
  • Dominik Bettinger, MD (PRINCIPAL_INVESTIGATOR) - University Hospital Freiburg
Contact Information
Study Contact:
Dominik Bettinger, MD
49761270-36870
dominik.bettinger@uniklinik-freiburg.de
Dominik Bettinger, MD
49761270-36870
dominik.bettinger@uniklinik-freiburg.de
University Medical Center Freiburg, Department of Medicine II
Dominik Bettinger, MD
University Medical Center Freiburg, Department of Medicine II
Interventions
  • Device: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) — For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
Study Locations (1 sites)
University Medical Center Freiburg, Department of Medicine II, Freiburg im Breisgau, 79106 Germany
Eligibility Criteria
Inclusion Criteria: * Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension Exclusion Criteria: * Withdrawal of written informed consent
Conditions Distress, Emotional, Emotional Dysfuncti...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to compare the effectiveness of three different skills trainings to cope with distress. These three trainings are: 1) an attention skills training, 2) an attention and reflective thought skills training, and 3) a health and wellness education training.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Online, Self-Directed Attention Skills Training with Coaching Support — The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
  • Behavioral: Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support — The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
  • Behavioral: Online, Self-Directed Health & Wellness Education Training with Coaching Support — The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.

Primary Outcomes

  • Changes in Ability to Regulate Emotions: Emotion Regulation Questionnaire (ERQ) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Changes in Ability to Distancing From Emotional Experience: Experiences Questionnaire (EQ) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Changes in Ability to Regulate Attention: Attentional Control Scale (ACS) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Changes in Ability to Regulate Attention in Emotional Contexts: Emotional Attentional Control Scale (eACS) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Changes in Approach-Avoidance Motivation: Mental Representation of Approach Avoidance Questionnaire (MRAAQ) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Changes in Positive and Negative Emotions: Modified Differential Emotions Scale (mDES) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
  • Change in Behavioral Dysregulation: Behavioral Dysregulation Scale (BDRS) (Pre-Training, Post-Training (6 weeks after starting the training), and 3-Month Follow-Up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-12
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Teachers College, Columbia University
Principal Investigators:
  • Douglas S Mennin, PhD (PRINCIPAL_INVESTIGATOR) - Teachers College, Columbia University
Contact Information
Study Contact:
Douglas S Mennin, PhD
212-678-6609
mennin@tc.columbia.edu
Douglas S Mennin, PhD
212-678-6609
mennin@tc.columbia.edu
Teachers College, Columbia University
Douglas S Mennin, PhD
Teachers College, Columbia University
Interventions
  • Behavioral: Online, Self-Directed Attention Skills Training with Coaching Support — The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
  • Behavioral: Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support — The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
  • Behavioral: Online, Self-Directed Health & Wellness Education Training with Coaching Support — The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
Study Locations (1 sites)
Teachers College, Columbia University, New York, New York 10027 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 18 and 65 * Fluent in English (and therefore able to provide consent) * Currently living in New York City * Access to a smartphone and the internet * High self-reported worry, rumination, and/or self-criticism * Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for at least one, current psychological disorder Exclusion Criteria: * Active suicidal ideation or intent * Substance dependence disorder, schizophrenia, bipolar-I disorder, or a primary DSM-5 diagnosis of borderline or narcissistic personality disorder * Individuals currently receiving therapy or psychosocial treatment who do not plan to continue with the same treatment throughout the study period * Individuals taking psychotropic mediation that has not been stabilized for a period of at least 3 months * Current students at Teachers College, Columbia University * Individuals with cardiac conditions, diagnosed hyperhidrosis, and traumatic brain injuries or other neurological conditions (e.g., dementia, Parkinson's, epilepsy)
Conditions Overweight, PreDiabetes, Diabetes Type 2...
Phase Not Applicable
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Dietary Supplement: Bariatrix Meal Replacement Products — Meal replacement products offered through the Massachusetts General Hospital Weight Center.

Primary Outcomes

  • Body weight reduction (3 months)
  • Hemoglobin A1c reduction (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-03-28
Completion: 2026-11-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Principal Investigators:
  • Chika V Anekwe, MD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Chika V Anekwe, MD
617-726-4400
canekwe@mgh.harvard.edu
Chika V Anekwe, MD
617-726-4400
canekwe@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Dietary Supplement: Bariatrix Meal Replacement Products — Meal replacement products offered through the Massachusetts General Hospital Weight Center.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-65 * Body mass index (BMI) greater than or equal to 27 kg/m\^2 * HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dL within the previous 6 months * Low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022 Exclusion Criteria: * Current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment * HbA1c greater than or equal to 10 percent * Plans to pursue bariatric surgery over the 6 months post-study enrollment * Weight loss of greater than 5 kg within the previous 3 months * Current active eating disorder, with the exception of binge eating disorder * Severe active psychiatric disease or significant cognitive impairment deemed by investigator likely to impede adherence to piloted intervention * Active illicit substance abuse * Pregnant, breastfeeding, or considering pregnancy within the next 6 months * Current participation in another clinical research trial deemed by investigator to conflict with current study
Conditions Ovarian Neoplasm, Depressive Symptoms, Q...
Phase NA
Enrollment 120
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will enroll 120 women living with ovarian cancer following completion of initial treatment. Our objective is to test an intervention designed to provide support during the survivorship transition for this population, who live with a high degree of morbidity related to the illness and its treatment as well as a high risk of recurrence. Study participants will be randomly assigned to receive survivorship care using the POSTCare-O process or usual care. The primary outcome is quality of life at 12 weeks after intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: POSTCare Survivorship transition process — Survivorship coaching intervention

Primary Outcomes

  • Quality of Life by FACT-O (12 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-01
Completion: 2027-04-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Collaborators: Cancer Prevention Research Institute of Texas, The University of Texas Health Science Center, Houston, University of Texas Southwestern Medical Center, University of Texas at Austin
Principal Investigators:
  • Elizabeth Kvale, MD,MPH (PRINCIPAL_INVESTIGATOR) - Baylor College of Medicine
Contact Information
Study Contact:
Nimrah Saleem, MPH
713-798-2272
nsaleem@bcm.edu
Judy Bettencourt, MPH
(713) 500-9527
judith.l.bettencourt@uth.tmc.edu
Carolina Salmeron
713-500-0147
Carolina.Salmeron@uth.tmc.edu
UT Southwestern Parkland Health and Hospital System
Interventions
  • Behavioral: POSTCare Survivorship transition process — Survivorship coaching intervention
Study Locations (3 sites)
UT Southwestern Parkland Health and Hospital System, Dallas, Texas 75235 United States
Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center, Houston, Texas 77030 United States
Harris Health Smith Clinic, Houston, Texas 77054 United States
Eligibility Criteria
Inclusion Criteria: * Stage 2-4 ovarian cancer * Treated with some combination of surgery, chemotherapy, biologics, maintenance therapy * Within 6 months of completion of initial treatment (continued maintenance therapy okay) * Able to provide consent in English or Spanish Exclusion Criteria: * Admission to hospice at the completion of treatment for ovary cancer